🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 60 of 173

  1. US 10335458

    Pharmaceutical compositions for treating or preventing bone conditions

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10335491

    Catalytic delivery nanosubstrates (CDNS) for highly efficient delivery of biomolecules

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10335368

    Ultrasound-triggerable agents for tissue engineering

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10336786

    Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10330600

    Plasmonic-magnetic bifunctional nanotubes for biological applications

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10329283

    G protein-coupled receptor kinase inhibitors and methods for use of the same

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10328161

    Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10329338

    Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10330685

    Markers for sepsis treatment

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10329356

    Fungal-specific metalloproteases and uses thereof

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10329353

    Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10329552

    Vaccine for livestock production systems

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10328109

    Targeted adenoviruses and methods of making, isolating, and using

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10328139

    Live-attenuated vaccine against plague

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10329326

    Melanocortin 1 receptor ligands and methods of use

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10328160

    Hollow silica nanospheres and methods of making same

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10328040

    Therapeutic methods

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10322113

    Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10322118

    Compounds and methods for inhibiting Cif virulence factor

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10323069

    Senecavirus A antigens and methods of use

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10322184

    Emulsions for intrapulmonary delivery

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10322171

    Vaccine with reduced enhancement of viral infection

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10323070

    VMP-like sequences of pathogenic Borrelia species and strains

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10322069

    Restorative resin compositions and methods of use

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10316073

    FCRN antagonists and methods of use

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10314860

    Compositions and methods for treating and preventing venom related poisoning

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10314885

    Oxytocin treatment to modify blood glucose and treat metabolic disease

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10314889

    Suppression of allergic lung inflammation and hyperreactivity

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10316050

    PT (IV) complexes containing 4,4′-disubstituted-2,2′-bipyridyl and their use in cancer therapy

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10314818

    Salinosporamides and methods of use thereof

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10314950

    Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10307407

    9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10307444

    Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10307437

    Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10308708

    Antibodies that neutralize botulinum neurotoxins

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10308961

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10307491

    Liposomal particles comprising biological molecules and uses thereof

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10308656

    Small molecule inhibitors of Ku70/80 and uses thereof

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10307449

    Compositions of polymeric myrcene

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10308638

    Selective alpha-7 nicotinic receptor agonists and methods for making and using them

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10307398

    Resuscitation composition and methods of making and using

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10307386

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10307428

    Therapeutic compositions for diabetic symmetrical polyneuropathy

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10300073

    Use of CDK9 and BRD4 inhibitors to inhibit inflammation

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10300152

    Enzyme-encapsulated nanoparticle platform

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10301320

    Compositions and methods of modulating 15-PGDH activity

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10300117

    Methods and compositions for improved cognition

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10300151

    Methods and systems for noninvasive fluorescence-based functional imaging of kidneys

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.